Sermorelin (GHRH 1-29)
Sermorelin (GHRH 1-29) scored 5.1 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Peptide → Growth / Repair Peptide.
Sermorelin (GHRH 1-29) is a short-acting peptide that prompts your own pituitary to release growth hormone, and it is the only one in its class with a former FDA approval and real human trials, per Thorner 1996. It scores Neutral because adult anti-aging data is thin and mixed, with a null body-composition trial per Vittone 1997.
What is Sermorelin (GHRH 1-29)?
Sermorelin is the synthetic 1-29 amino-acid fragment of growth-hormone-releasing hormone, the shortest piece of the natural signal that still tells your pituitary to fire off a pulse of growth hormone. Instead of injecting growth hormone directly, you nudge your own gland to release it the way it normally would, in a brief burst that rises and falls. That keeps your natural feedback brakes in place, which is the whole pitch for calling it more physiological than recombinant HGH. The reason it lands at the top of the short-acting growth-hormone-peptide group, at Neutral, is simple: it is the only one in its class that was actually FDA-approved, sold as Geref, and tested in real human trials, per Thorner 1996.
Here's the honest catch. The solid trials were in growth-hormone-deficient children, not aging adults chasing better sleep and body composition. The modern adult anti-aging data is thin, dated, small, and frequently mixed, including a study that found no change in body fat or muscle at all, per Vittone 1997. On top of that, Geref was pulled from the US market in 2008, and not for safety, so today the only sermorelin you can get is compounded, sitting in a grey-market zone. The hormone reliably rises on the lab bench. Whether that turns into the benefits people buy it for is where the evidence gets shaky.
Terminology
A few terms decide how you read this report, because the gap between "the hormone goes up" and "the outcome is proven" is exactly where sermorelin lives, and because the growth-hormone-peptide world is full of look-alike names that get mixed up constantly. The single most important distinction is between a GHRH, which sermorelin is, and a GHRP, which it is almost always stacked with. They sound similar and both raise growth hormone, but they hit different receptors and play different roles. The second distinction that matters is between the hormone markers, growth hormone and IGF-1, which reliably rise, and the real-world outcomes like fat loss or better sleep, which do not reliably follow. Keep those two pairs straight and the whole report reads cleanly. Here are the terms worth knowing before you go further.
- GHRH: Growth-hormone-releasing hormone. The natural brain signal that tells the pituitary to release growth hormone. Sermorelin is a fragment of it.
- GHRH 1-29 / GRF(1-29): The first 29 amino acids of GHRH, the shortest fragment that keeps full activity. This is sermorelin.
- Pulsatile release: Your body puts out growth hormone in short bursts, not a steady stream. Sermorelin amplifies those bursts rather than flooding the system.
- GH: Growth hormone itself. The pituitary hormone sermorelin prompts your body to release.
- IGF-1: Insulin-like growth factor 1. The downstream hormone that growth hormone produces, the marker users track, and the pathway behind the long-term cancer caution.
- GHRP: Growth-hormone-releasing peptide, such as ipamorelin or GHRP-2. A different class that hits the ghrelin receptor; almost always stacked with sermorelin for a bigger combined pulse.
- Geref: The former FDA-approved brand name for sermorelin acetate, discontinued in 2008.
- Somatopause: The age-related decline in growth-hormone output that makes older adults the most logical candidates.
- Tesamorelin: A modern, FDA-approved GHRH analogue with newer trials. The better-evidenced cousin in this family.
How do you take Sermorelin (GHRH 1-29)?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 1 route and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Subcutaneous injection | Lyophilized powder reconstituted with bacteriostatic water | Pediatric approved dose was 30 mcg/kg nightly; diagnostic test dose was 1 mcg/kg intravenous | About 100 to 300 mcg pre-sleep, fasted, often with a GHRP |
Protocols
Conservative starter Anecdotal
- Dose
- 100 mcg
- Frequency
- Once nightly
- Duration
- 8 to 12 weeks
Pre-sleep and fasted, timed to the natural overnight growth-hormone pulse. The gentlest entry point into GH-axis peptides.
Standard adult anti-aging Anecdotal
- Dose
- 200 to 300 mcg
- Frequency
- Once nightly
- Duration
- 3 to 6 month courses, often 5 days on and 2 off
Cycling is common to limit receptor downregulation. Single-nightly fixed dosing was less effective than divided dosing in the adult research, per Vittone 1997. Not an approved dose.
Sermorelin plus a GHRP (dominant clinic pattern) Anecdotal
- Dose
- 100 to 300 mcg sermorelin plus a GHRP such as ipamorelin
- Frequency
- Once to twice daily
- Duration
- 8 to 12 weeks per cycle
A GHRH plus a ghrelin-mimetic hit two complementary pathways for a larger combined pulse than either alone. The synergy is mechanistically grounded and clinic-standard, not proven for this exact pair in a human outcome trial.
Verified-study calibration (NOT an anti-aging dose) Clinical
- Dose
- 10 mcg/kg to 30 mcg/kg nightly, or 0.5 to 2 mg twice daily in research
- Frequency
- Per study protocol
- Duration
- 6 weeks to 12 months in the trials
For reference only. Pediatric growth used 30 mcg/kg nightly, per Thorner 1996; adult research used weight-based or fixed milligram doses, per Khorram 1997 and Vittone 1997. These are not adult anti-aging protocols.
How this score is calculated →
What are the benefits of Sermorelin (GHRH 1-29)?
Upside contribution: 1.89
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.8 | 0.700 | |
| Breadth | 15% | 2.8 | 0.420 | |
| Evidence | 25% | 3.2 | 0.800 | |
| Speed | 10% | 3.2 | 0.320 | |
| Durability | 10% | 2.0 | 0.200 | |
| Bioindividuality | 15% | 3.0 | 0.450 | |
| Total | 2.890 |
Upside Rationale
The upside for sermorelin is real but concentrated in pedigree and mechanism rather than proven adult outcomes. Its single biggest asset is that, unlike the rest of the short-acting GHRH peptides people run, it was genuinely FDA-approved and carries dedicated human trials, per Thorner 1996. The mechanism is clean and well-characterized, and the hormone response is reproducible across decades of studies. The boundary condition that keeps every dimension modest is the same one: the dependable evidence is pediatric, and the adult anti-aging outcomes are small, old, and split between a positive lean-mass result and a flat null. Evidence is the dimension that lifts sermorelin above its peers; efficacy and durability are what cap it.
Efficacy (2.8/5.0): Efficacy is moderate because the hormone response is dependable while the downstream adult benefits are not. The clearest positive adult result came from a 16-week study of a stabilized GHRH 1-29 analog at 10 mcg/kg nightly, which raised lean body mass, well-being, and libido in older men, with skin thickness up in both sexes, per Khorram 1997. Women in that study gained no lean mass, so the effect is sex-dependent. Pull the other direction and you get a 6-week study at 2 mg nightly with no change in weight, waist-to-hip, or DEXA fat and muscle, and no IGF-1 rise at all, per Vittone 1997. In children, head-to-head it was consistently weaker than recombinant growth hormone for promoting growth, per Chen 1993. The hormone moves reliably; the body does not move reliably.
Breadth of Benefits (2.8/5.0): Breadth is moderate because the growth-hormone axis plausibly touches many systems while few are proven for sermorelin specifically. The axis influences body composition, recovery, sleep, skin, and bone in theory, and the human work confirms the upstream signal moves: growth hormone and IGF-1 rose toward young-adult levels in older men, per Corpas 1992, and skin thickness increased in both sexes, per Khorram 1997. The limit is that breadth of mechanism is not breadth of proof. In adults, no system has a clean controlled sermorelin endpoint with a consistent positive result, and the strongest modern hard-endpoint data in this whole family belongs to tesamorelin, a different analogue, not to sermorelin.
Evidence Quality (3.2/5.0): Evidence quality is the dimension that lifts sermorelin above its short-acting peers, and the reason it tops the group. It has real human RCTs and a former FDA approval, neither of which the no-DAC peptides can claim. The pediatric file is genuinely solid: a 110-patient pivotal trial plus a randomized head-to-head against growth hormone, per Thorner 1996. What holds the score back is that the dependable data is pediatric, and the adult anti-aging studies are old, small, and mixed: positive on lean mass in one, per Khorram 1997, but null on body composition in another, per Vittone 1997. There is no large, modern, placebo-controlled adult outcome trial, which is what separates it from tesamorelin.
Speed of Onset (3.2/5.0): Speed is a relative bright spot. The growth-hormone pulse fires within minutes of a subcutaneous dose, since the molecule acts fast and clears fast. On the hormone markers, nocturnal growth hormone and IGF-1 rose within about 2 weeks in older adults, per Khorram 1997. Subjectively, the most common report is deeper sleep within the first weeks, with recovery and any body-composition change described over 2 to 3 months. The fast hormonal action is well-supported; the fast felt effect is anecdotal and overlaps exactly with the endpoints where controlled data is weakest.
Durability (2.0/5.0): Durability is low because the benefit is transient by design. The short half-life means the pulse is discrete with no carryover reservoir, so any effect fades when you stop. That fade was shown directly in children, where growth gains reversed off-drug, per Kirk 1994. Worse, continuous use can blunt the response over time: growth-hormone responsiveness to GHRH declined over 12 months of continuous pediatric dosing in that same study, which is why people cycle. This is a maintain-to-keep-it tool, not a one-and-done reset, and continuous use can quietly lose potency.
Bioindividuality Upside (3.0/5.0): Response varies enough that some people notice clearly more than others, which lifts this dimension. The best candidates are older adults with low baseline growth-hormone output or documented low IGF-1, the group where GHRH 1-29 restored the age-related decline most clearly, per Corpas 1992. Sex is another axis of variation: the 16-week analog study saw lean-mass and well-being gains in men but not women, per Khorram 1997. So predictable modifiers exist, which is good, but they also mean younger people with a healthy axis and many women may feel little.
What are the risks & downsides of Sermorelin (GHRH 1-29)?
Downside contribution: 1.81 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 2.6 | 0.780 | |
| Side effects | 15% | 2.2 | 0.330 | |
| Cost | 5% | 2.6 | 0.130 | |
| Effort | 5% | 3.2 | 0.160 | |
| Opportunity | 5% | 3.0 | 0.150 | |
| Dependency | 15% | 2.5 | 0.375 | |
| Reversibility | 25% | 1.8 | 0.450 | |
| Total | 2.375 | |||
| Harm subtotal × 1.4 | 2.709 | |||
| Opportunity subtotal × 1.0 | 0.440 | |||
| Combined downside | 3.149 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.809 |
Downside Rationale
The downside for sermorelin is dominated by uncertainty, opportunity cost, and an easy-to-stop-but-easy-to-lose profile rather than acute danger. The molecule itself is clean: across the trials the worst common effects were transient flushing and injection-site pain, per Thorner 1996, with no intrinsic fatal signal. The heavier weights come from a real opportunity cost, since tesamorelin does a similar job with modern trials behind it, and from the grey-market sourcing that shifts the dominant risk to product quality. Dependency is low and reversibility is excellent, but that same fast clearance is why the durability dimension scores poorly. Who is most exposed: people with cancer risk via the IGF-1 pathway, and anyone buying from an unverified compounding source.
Safety Risk (2.6/5.0): Safety risk is moderate, driven by class-level theory and sourcing rather than a confirmed catastrophic signal. The growth-hormone-releasing class is clean in practice: the common effects are injection-site reactions and flushing, with no major signal in the verified trials, per Thorner 1996. There is no intrinsic fatal mechanism. The theoretical concerns are growth-hormone biology. It raises IGF-1, per Khorram 1997, which feeds the long-term cancer caution that applies to the whole axis, so active cancer is an absolute contraindication. Glucose can drift up, since growth hormone opposes insulin, with pediatric data showing fasting glucose and insulin rose, per Kirk 1994. Because today's product is compounded, the dominant real-world risk is product quality, purity, and dosing accuracy, not the molecule.
Side Effect Profile (2.2/5.0): Side effects are mild and the favorable part of the profile, often described as the gentlest GHRH option. The signature complaints are transient facial flushing and injection-site pain or redness, per Thorner 1996. Headache, nausea, dizziness, and occasional water retention or vivid dreams show up less commonly. Most fade with continued use or a small dose reduction, and the short half-life means anything bothersome passes within hours rather than lingering. The score reflects a genuinely tolerable molecule, with the main caveat being unpredictability from compounded product quality.
Financial Cost (2.6/5.0): Cost is moderate and recurring rather than steep. Compounded sermorelin is relatively cheap per vial, especially through telehealth and anti-aging clinics that often sell it on subscription. The real spend comes from daily dosing, the near-standard GHRP add-on, and IGF-1 testing, which together push a real cycle toward a few hundred dollars a month. It is not expensive per dose; the ongoing outlay on a thinly-proven adult use is the framing that matters.
Time/Effort Burden (3.2/5.0): Effort is meaningful. Sermorelin needs reconstitution with bacteriostatic water, a subcutaneous injection done fasted and pre-sleep, careful timing around food, cold storage after mixing, and site rotation. Add the common GHRP stack and you are often managing two peptides and frequent cycling. That is a real daily logistics load compared with an oral supplement, and the fasted-timing rules add friction most people underestimate.
Opportunity Cost (3.0/5.0): Opportunity cost is genuine and higher than for most peptides in this family, because a better-evidenced option exists. Tesamorelin shares the same short, pulsatile kinetics, holds a current FDA approval, and has modern placebo-controlled trials with hard endpoints, where sermorelin's adult file is old and mixed. Money and effort spent on sermorelin could go there, or to the training, protein, and sleep basics that move the same goals with far more certainty. The counterweight is access: sermorelin is cheaper and easier to obtain than branded tesamorelin.
Dependency/Withdrawal (2.5/5.0): Dependency risk is low. Sermorelin amplifies your own pulsatile growth hormone and does not shut down a hormonal axis the way exogenous growth hormone can, so benefits simply fade when you stop, which is functional reliance rather than withdrawal. The open question is receptor desensitization with long continuous use, the documented basis for cycling, since responsiveness fell over 12 months of continuous dosing, per Kirk 1994. There is no addiction or withdrawal syndrome.
Reversibility (1.8/5.0): Reversibility is excellent and a genuine strength. The roughly 10 to 20 minute half-life means a bad reaction or unwanted effect clears within minutes to hours, and stopping returns the growth-hormone axis to baseline with no taper and no lasting change. You can quit cleanly any time. The flip side of that same fast clearance is the poor durability score: nothing carries over, so the benefit needs continuous dosing to persist.
Sermorelin is the rare research-grey peptide that once held a real FDA approval, which is exactly why it tops its class while still landing at Neutral. The pedigree is real; the modern adult proof is not. Nick Urban, drawing on the pivotal pediatric trial, per Thorner 1996
The most-marketed benefit, better sleep, has the thinnest and least flattering direct data of all. The one small aging sleep study found no growth-hormone boost and worse sleep, so judge it on your own response, not the sales page. Nick Urban, on the negative aging sleep result, per Murck 1997
Is Sermorelin (GHRH 1-29) worth it?
Sermorelin earns its Neutral score by being the most credentialed peptide in a thinly-proven class, not by having strong adult outcome data. If you are an older adult with documented low IGF-1 or age-related somatopause, you want the GHRH peptide with the most regulatory pedigree, and you accept that the modern adult evidence is mixed, it is a reasonable, low-drama experiment, especially stacked with a GHRP. If you expect proven fat loss or guaranteed better sleep, the data is not there, and the better-supported path is tesamorelin. The two biggest real-world frictions are grey-market sourcing quality and the fact that benefits fade the moment you stop. The fairest way to think about it: sermorelin is the safest-feeling, best-documented way to gently nudge your own growth-hormone output, but the proof that nudging it helps a healthy aging adult is still missing. That is exactly what a Neutral score means. It is not a mistake to try and not a slam dunk to recommend. Judge it on your own response over a few weeks of consistent, fasted, pre-sleep dosing, track your IGF-1 and fasting glucose, and stop without ceremony if nothing moves.
✅ Best for: Older adults with low baseline growth-hormone output or documented low IGF-1, the group that responded most clearly to GHRH 1-29, per Corpas 1992. Men in particular, since the one positive adult lean-mass result was male-only, per Khorram 1997. People who want the gentlest, most credentialed entry point into growth-hormone peptides and will judge it on their own response over a few weeks. Anyone who can verify pharmaceutical-grade compounded material with a certificate of analysis. Users who already have training, protein, and sleep dialed in and want a low-suppression add-on rather than a foundation.
❌ Avoid if: You have active or hormone-sensitive cancer, since growth-hormone and IGF-1 signaling can drive proliferation, an absolute contraindication. You are pregnant or breastfeeding, with no safety data. You have uncontrolled diabetes or insulin resistance, because growth hormone opposes insulin and fasting glucose can rise, per Kirk 1994. You compete in tested sport, since growth-hormone-releasing factors are banned at all times under WADA category S2. You cannot verify your source, because compounded and research-chemical sermorelin vary in purity and dose, and that quality gap can exceed the intrinsic risk of the molecule.
What is Sermorelin (GHRH 1-29) best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| ○ Body Composition / Fat Loss Primary | 4.2 | Body composition is sermorelin's best-supported adult use, and it still scores only modestly because the human data is genuinely split. The strongest positive came from a 16-week study of a stabilized GHRH 1-29 analogue at 10 mcg/kg nightly, which raised lean body mass and well-being in older men, per Khorram 1997, though women gained no lean mass. Against that, a 6-week study at 2 mg nightly found no change in weight, waist-to-hip, or DEXA fat and muscle, and IGF-1 did not even rise, per Vittone 1997. The split tracks dose and regimen: weight-based, longer dosing helped, while a single fixed nightly dose did not. There is no large modern trial, so the honest read is small, inconsistent, and sex-dependent. |
| ○ Recovery / Repair Primary | 4.0 | Recovery is one of the most consistently reported real-world wins, but it rests on growth-hormone and IGF-1 physiology rather than a controlled human recovery trial of sermorelin. GHRH 1-29 reliably raises 24-hour growth hormone and IGF-1 in older adults back toward young-adult levels, per Corpas 1992, and that hormonal signal is the plausible mechanism behind faster soft-tissue repair. The catch is that no study measured recovery, injury healing, or training adaptation as an endpoint in adults using sermorelin. The score reflects a real and reproducible upstream hormone effect paired with an absent downstream recovery outcome, which is why it lands modest rather than high. |
| ○ Sleep Quality Primary | 4.0 | Sleep is the single most popular reason people run sermorelin, yet the controlled adult evidence is weak to negative, which keeps the score modest. GHRH at the class level can promote deep, non-REM sleep in human paradigms, the mechanistic basis for the anecdotal reports. But the one small sermorelin-specific aging sleep study was a preliminary two-person priming experiment that found no growth-hormone enhancement and actually worse sleep quality in the elderly, per Murck 1997. So the most-marketed benefit has the thinnest and least flattering direct data. The score gives partial credit for the strong class-level mechanism and consistent community reports while penalizing the absent or negative sermorelin-specific outcome. |
Frequently Asked Questions
What is sermorelin and how does it work?
Sermorelin is the synthetic 1-29 amino-acid fragment of growth-hormone-releasing hormone, the shortest piece that still tells your pituitary to release a natural pulse of growth hormone. It activates the GHRH receptor and amplifies your own episodic growth-hormone release rather than supplying outside hormone, so your natural feedback brakes stay intact. That feedback-preserved design is the basis for calling it more physiological than recombinant HGH. Even short courses restored age-blunted growth hormone and IGF-1 to young-adult levels in older men, per Corpas 1992.
How do people dose sermorelin, and when?
Adult anti-aging protocols commonly run about 100 to 300 mcg subcutaneously once nightly, fasted and pre-sleep, often stacked with a GHRP and cycled in 3 to 6 month courses. These are not approved doses. The only approved regimen was the pediatric 30 mcg/kg nightly dose, per Thorner 1996. Timing matters because food, insulin, and somatostatin tone all blunt the response, which is why empty-stomach and bedtime dosing is standard. Single fixed nightly dosing looked weaker than divided dosing in adult research, per Vittone 1997.
Was sermorelin ever FDA-approved, and why was it discontinued?
Yes, sermorelin was FDA-approved as Geref for pediatric growth-hormone-deficiency diagnosis and treatment, supported by real trials, per Thorner 1996. The manufacturer discontinued it for commercial reasons tied to sourcing the active ingredient, not safety or effectiveness, and the FDA later confirmed in a Federal Register notice that it was not withdrawn for safety. Because of that, compounded versions remain legal. So today it is compounded-only and sits in a grey-market zone, which shifts the main risk from the molecule to product quality.
Does sermorelin actually work for anti-aging in adults?
The honest answer is the adult anti-aging evidence is thin, dated, and mixed. A 16-week study of a stabilized GHRH 1-29 analog raised lean mass and well-being in older men, per Khorram 1997, but a 6-week study found no change in body composition and no IGF-1 rise, per Vittone 1997, and a small sleep priming study was outright negative, per Murck 1997. The hormone reliably rises; the downstream outcomes are inconsistent. There is no large modern placebo-controlled adult trial.
Is sermorelin safe?
Sermorelin has a clean profile across the trials, with the most common effects being transient facial flushing and injection-site pain, per Thorner 1996. There is no intrinsic fatal signal in the verified studies. The theoretical concerns are class-level: it raises IGF-1, which feeds the long-term cancer caution that applies to the whole growth-hormone axis, and it can nudge glucose. Because today's product is compounded, the dominant practical risk is product quality, purity, and dosing accuracy rather than the molecule itself.
Who should avoid sermorelin?
Anyone with active or hormone-sensitive cancer should avoid sermorelin, since growth-hormone-axis stimulation can drive proliferation, and that is an absolute contraindication. Pregnancy and breastfeeding are off-limits given no safety data, and uncontrolled diabetes or insulin resistance is a caution because growth hormone opposes insulin, per Kirk 1994. Competitive athletes must avoid it too: it is banned in tested sport at all times under WADA category S2. Anyone who cannot verify a quality compounded source should also wait.
How long until sermorelin works?
The growth-hormone pulse itself is fast, firing within minutes of an injection, and nocturnal growth hormone and IGF-1 rose within about 2 weeks in the adult analog study, per Khorram 1997. Subjectively, the most common report is deeper sleep within the first weeks, with recovery and any body-composition change described over 2 to 3 months. None of these timelines come from a large controlled trial, so treat the felt effects as community expectations rather than proven onset windows.
How does sermorelin compare to CJC-1295, ipamorelin, and tesamorelin?
Sermorelin sits at the top of the short-acting GHRH group on regulatory pedigree. It edges out CJC-1295 no-DAC because it had a real FDA approval and human trials, where the no-DAC form has none. It runs about level with ipamorelin, which is a GHRP rather than a GHRH and is usually stacked with it. It sits below tesamorelin, which has modern placebo-controlled trials and a current FDA approval. For most people the practical pairing is sermorelin plus a GHRP.
What could change Sermorelin (GHRH 1-29)'s score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
The fastest path up is a modern, well-powered adult outcome trial, and the fastest path down is a credible safety signal or a clean null in a large study. Because the current score rests on old, small, mixed adult data sitting on top of a solid pediatric and regulatory base, even one good modern trial in either direction would move it more than usual. The dimensions most likely to shift first are Efficacy and Evidence together, since they are the ones held back by the thin adult file. The realistic catch is that sermorelin is unlikely to get that trial: the field's modern growth-hormone-releasing research momentum has moved to tesamorelin, which already has the approval and the funding, so most new GHRH outcome data will carry tesamorelin's name rather than sermorelin's. That means the score could stay parked at Neutral for a long time simply through neglect, not because the question was answered. A regulatory shift, either a crackdown that removes compounded access or a fresh approval that restores it, is the more probable mover. Here is how the most plausible scenarios would reshape the dimensions.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| A modern placebo-controlled adult trial shows real body-composition or sleep benefit | Efficacy 2.8 to 3.6, Evidence 3.2 to 4.0 | 5.6 / 10 ⚖️ Neutral |
| A head-to-head confirms sermorelin plus a GHRP beats either alone | Efficacy 2.8 to 3.3, Breadth 2.8 to 3.3 | 5.4 / 10 ⚖️ Neutral |
| Sermorelin regains a standing FDA approval for an adult indication | Evidence 3.2 to 3.8, Safety 2.6 to 2.4 | 5.4 / 10 ⚖️ Neutral |
| A large modern adult trial fails to beat placebo for a marketed use | Efficacy 2.8 to 2.2, Evidence 3.2 to 2.8 | 4.8 / 10 ⚖️ Neutral |
| A credible cancer or metabolic harm signal emerges in the class | Safety 2.6 to 4.0, Evidence 3.2 to 3.0 | 4.5 / 10 ⚖️ Neutral |
| Compounding crackdown removes legal access and quality stays unverified | Cost 2.6 to 3.4, Safety 2.6 to 3.2 | 4.8 / 10 ⚖️ Neutral |
Key Evidence Sources
- Thorner 1996, J Clin Endocrinol Metab: GHRH 1-29 at 30 mcg/kg nightly raised height velocity from 4.1 to 8.0 cm/yr at 6 months in 110 prepubertal growth-hormone-deficient children, with 74 percent good responders.. Pivotal pediatric efficacy RCT (1996) behind the Geref FDA approval; 110 patients, no excess IGF-1 or glucose change.
- Chen 1993, Acta Paediatr Suppl: randomized 6-month trial of GHRH 1-29 at 30 or 60 mcg/kg/day versus growth hormone in 60 children with hypothalamic growth-hormone deficiency.. Head-to-head RCT (1993) showing GHRH height velocity of 9.2 to 9.3 cm/yr versus 14.6 for growth hormone; GH significantly superior.
- Kirk 1994, Clin Endocrinol: open 12-month study of GHRH 1-29 at 20 mcg/kg twice daily in 18 children with idiopathic short stature.. 12-month study (1994); height velocity rose 4.8 to 7.2 cm/yr, fasting glucose and insulin rose, effect reversed off-drug.
- Corpas 1992, J Clin Endocrinol Metab: GHRH 1-29 at 0.5 to 1 mg twice daily for 14 days reversed age-related growth-hormone and IGF-1 decline in older men toward young-adult levels.. Crossover trial (1992); strongest adult datapoint that the somatotroph axis stays responsive to GHRH with age.
- Khorram 1997, J Clin Endocrinol Metab: stabilized GHRH 1-29 analog at 10 mcg/kg nightly for 16 weeks raised lean body mass, well-being, and skin thickness in older men, with no lean-mass gain in women.. 16-week adult RCT (1997); positive lean-mass and well-being result, sex-dependent, on a closely related stabilized analog.
- Vittone 1997, Metabolism: GHRH 1-29 at 2 mg single nightly dose for 6 weeks in 11 older men produced no change in body composition and no IGF-1 rise.. 6-week adult study (1997); null body-composition result, single nightly dosing judged less effective than divided dosing.
- Murck 1997, Pharmacopsychiatry: GHRH priming over 12 days in 2 elderly men did not restore sleep-endocrine efficiency and sleep quality decreased.. Preliminary aging sleep study (1997); negative result on the most-marketed sermorelin benefit.
- WADA 2026 Prohibited List: growth-hormone-releasing factors including sermorelin are prohibited at all times under category S2.. Anti-doping status (2026 list); sermorelin named alongside CJC-1295 and tesamorelin under S2.2.4.
What does the evidence say about Sermorelin (GHRH 1-29)?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Thorner 1996, Corpas 1992, Khorram 1997, Vittone 1997, Murck 1997
Holistic Evidence for Sermorelin (GHRH 1-29)
Sermorelin is a synthetic peptide with no traditional or historical medical lineage, so only the modern-science lens applies. Within that lens, the upstream hormone effect is consistent while the downstream adult outcomes are split.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- IGF 1 Pre | Expected Watch During | Expected Up
- Fasting Glucose During | Expected Watch
Pulse Dimensions to Watch
- Sleep During | Expected Up | Primary
- Body During | Expected Watch | Secondary
- Energy During | Expected Up | Tertiary
Subjective Signals (Daily Voice Card)
- Sleep depth and morning grogginess Scale 1-5 | During | Expected Up
- Flushing, facial warmth, or injection-site redness after dosing Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Progressive or worsening reaction with each injection (possible sensitization): stop immediately.
- New or worsening numbness or tingling (possible fluid-related nerve compression): reduce dose or stop.
- Rising fasting glucose: stop and consult a clinician, especially with diabetes or insulin resistance.
- Any active or suspected cancer: do not use; growth-hormone-axis stimulation is contraindicated.
Other interventions for Body Composition
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.890 − 1.809 = 0.081
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.081 / 5) × 5 = 5.1 / 10
